>opioid alternative for acute and chornic pain
>less tolerance
>less dependance because of a polymodal action
>B*g Ph*rma been trying to retard its approval date for years because it would replace classical opioid analgesics on a global scale
Developer is Grünenthal, German corp.
-> Based on the pharmacology and pharmacokinetics, cebranopadol does appear to be a promising alternative to traditional opioids. The potential for reduced tolerance and dependence with NOP activation demonstrated in animal models, combined with a prolonged half-life and reduced likeability in human subjects make cebranopadol especially appealing for chronic pain management.(2,4,5,8,16)
Clinical trials have produced significant results for pain reduction in acute postoperative pain, chronic low back pain, and osteoarthritic pain, however, the data supporting the use of cebranopadol for DPN is currently lacking. We look forward to the publication of the results of the trials that have been completed but not yet published. Chronic use of cebranopadol up to 26 weeks appears to be safe, however, the high rates of TEAEs and participant dropout rate from the chronic low back pain study are concerning.11,17
The timeline for this drug's approval, both internationally and in the United States, is unclear. Further studies examining the safety, efficacy, and potential for abuse will be helpful in determining if cebranopadol can one day be considered the “Holy Grail” of opioids. For now, this investigational product may be considered a unique opioid product with intriguing implications for pain management.
https://www.practicalpainmanagement.com/treatments/pharmacological/non-opioids/analgesics-future-cebranopadol-opioid-alternative
https://jpet.aspetjournals.org/content/349/3/535/tab-figures-data
>less tolerance
>less dependance because of a polymodal action
>B*g Ph*rma been trying to retard its approval date for years because it would replace classical opioid analgesics on a global scale
Developer is Grünenthal, German corp.
-> Based on the pharmacology and pharmacokinetics, cebranopadol does appear to be a promising alternative to traditional opioids. The potential for reduced tolerance and dependence with NOP activation demonstrated in animal models, combined with a prolonged half-life and reduced likeability in human subjects make cebranopadol especially appealing for chronic pain management.(2,4,5,8,16)
Clinical trials have produced significant results for pain reduction in acute postoperative pain, chronic low back pain, and osteoarthritic pain, however, the data supporting the use of cebranopadol for DPN is currently lacking. We look forward to the publication of the results of the trials that have been completed but not yet published. Chronic use of cebranopadol up to 26 weeks appears to be safe, however, the high rates of TEAEs and participant dropout rate from the chronic low back pain study are concerning.11,17
The timeline for this drug's approval, both internationally and in the United States, is unclear. Further studies examining the safety, efficacy, and potential for abuse will be helpful in determining if cebranopadol can one day be considered the “Holy Grail” of opioids. For now, this investigational product may be considered a unique opioid product with intriguing implications for pain management.
https://www.practicalpainmanagement.com/treatments/pharmacological/non-opioids/analgesics-future-cebranopadol-opioid-alternative
https://jpet.aspetjournals.org/content/349/3/535/tab-figures-data
